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Abstract
Objectives: In Peru, a country with constrained health resources, breast cancer control is characterized by late stage
treatment and poor survival. To support breast cancer control in Peru, this study aims to determine the cost-
effectiveness of different breast cancer control interventions relevant for the Peruvian context.
Methods: We performed a cost-effectiveness analysis (CEA) according to WHO-CHOICE guidelines, from a
healthcare perspective. Different screening, early detection, palliative, and treatment interventions were evaluated
using mathematical modeling. Effectiveness estimates were based on observational studies, modeling, and on
information from Instituto Nacional de Enfermedades Neoplásicas (INEN). Resource utilizations and unit costs were
based on estimates from INEN and observational studies. Cost-effectiveness estimates are in 2012 United States
dollars (US$) per disability adjusted life year (DALY) averted.
Results: The current breast cancer program in Peru ($8,426 per DALY averted) could be improved through
implementing triennial or biennial screening strategies. These strategies seem the most cost-effective in Peru,
particularly when mobile mammography is applied (from $4,125 per DALY averted), or when both CBE screening
and mammography screening are combined (from $4,239 per DALY averted). Triennially, these interventions costs
between $63 million and $72 million per year. Late stage treatment, trastuzumab therapy and annual screening
strategies are the least cost-effective.
Conclusions: Our analysis suggests that breast cancer control in Peru should be oriented towards early detection
through combining fixed and mobile mammography screening (age 45-69) triennially. However, a phased
introduction of triennial CBE screening (age 40-69) with upfront FNA in non-urban settings, and both CBE (age
40-49) and fixed mammography screening (age 50-69) in urban settings, seems a more feasible option and is also
cost-effective. The implementation of this intervention is only meaningful if awareness raising, diagnostic, referral,
treatment and basic palliative services are simultaneously improved, and if financial and organizational barriers to
these services are reduced.
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Introduction
In Peru and other Latin-American countries, cancers have
become a pressing health concern over the last decades.
Cancer incidence and mortality rates have been rising and will
probably continue to rise as a result of population growth,
aging, urbanization and lifestyle changes [1-4].
In Peru, the highest cancer burden is currently represented
by stomach, cervix, breast, prostate and lung cancer. Breast
cancer is, together with cervical cancer, the leading cancer
among females in terms of mortality and incidence [5,6]. Breast
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cancer has shown a persistent increase in incidence over the
last decades, and many women present in advanced breast
cancer stages. Efforts to control the disease in Peru are
therefore essential (Table 1) [6,7].
As a public response, the Peruvian Ministry of Health
(MINSA) and allied institutions developed multi-sectoral cancer
control strategies in 2006, focusing on prevention, education,
early detection and expanding services for multiple cancers [8].
The strategic program, explicitly for breast cancer, consists of
group and individual counseling in breast cancer prevention
(women aged 18 to 64 years) as well as the promotion of
annual mammography screening (age group 40-65).
Furthermore, with the goal of reaching universal coverage, the
Peruvian government introduced a universal health insurance
law in 2009 and has also gradually been devoting more
financial resources to cancer control [9-11].
Despite these developments, the implementing institutions
face significant problems with the roll out of cancer control
strategies. The coverage of breast cancer services is only
partial and unequal, partly due to a fragmented health system,
decentralization, and the unguaranteed financial resources
[12]. In addition, only 51.8% of the population was insured
(INEI 2008) and breast cancer treatment and rehabilitation,
only partially covered by insurance, may require substantial out
of pocket payments [13]. This may lead to important financial,
cultural and geographical disparities in access to breast cancer
care for many Peruvian women [14].
With this background, and with the rising cost of cancer
control to the Peruvian healthcare system, MINSA is facing
difficult choices on which breast effective cancer interventions
to provide and at which cost they can be sustained for the long
term. Also, given its limited health-care resources, Peru needs
to spend money wisely and fund interventions that provide best
value for money. Cost-effectiveness analysis (CEA) is a tool
that systematically compares costs and effects of health
interventions and that can guide policy makers in these
decisions. Results from CEAs can for example be used to
improve the general planning of strategies, or to strengthen
certain breast cancer strategies by demonstrating their value
for money. So far, CEAs on breast cancer interventions have
not been conducted in Peru [15], hence, important information
on efficient breast cancer control strategies is currently lacking.
To support breast cancer control in Peru, this study aims to
explore and report the cost-effectiveness of different breast
cancer control interventions relevant for the Peruvian context.
In this paper, we provide an outline of the most efficient and
feasible interventions for breast cancer control in Peru from the
healthcare perspective.
Methods
General approach
Our standardized CEA methods, derived from WHO-
CHOICE, are described in detail elsewhere and build on
previous regional and country specific analyses of interventions
to control breast cancer [16-20]. An important feature of this
methodology is that all possible interventions are compared to
a situation where no interventions are implemented. This
counterfactual acts as a reference to compare the cost and
effects of all possible interventions, and enables us to make
comparisons across a wide range of competing interventions
(e.g. tuberculosis, mental disorders, non-communicable
diseases) [16,21-24].
Breast cancer data and interventions
To select a set of breast cancer interventions relevant to
Peru and to identify sources for cost and effectiveness data, a
local study team was established during a stakeholder meeting
in 2011. The team, consisting of representatives from the
Ministry of Health (MoH), the national cancer institute (INEN),
the social security network (EsSalud), PATH, and the World
Health Organization (WHO/PAHO), could propose any type of
breast cancer intervention.
An assessment tool, to collect information on breast cancer
programs and their coverage, finance, and epidemiology, was
Table 1. Age distribution of breast cancer incidence and mortality in Peru.
Age groups   
Female
population (2005)*
Incidence rate
per 100.000)*
Number of incident
cases (%)
Mortality rate
(per 100.000)*
Number of deaths
(%)   
Mortality /
incidence ratio
Current stage
distribution (AJCC)**
0-4 1,382,448 0.0 0 (0%) 0.0 0 (0%) n/a Stage I
5-14 2,860,994 0.0 0 (0%) 0.0 0 (0%) n/a 7.04%
15-29 3,801,363 1.28 49 (1.4%) 0.25 10 (0.5%) 0.20 Stage II
30-44 2,736,393 31.69 867 (24.2%) 9.66 264 (12.7%) 0.30 36.44%
45-59 1,654,473 85.79 1419 (39.6%) 46.22 765 (36.7%) 0.54 Stage III
60-69 630,326 85.17 536 (15.0%) 64.45 406 (19.5%) 0.76 43.48%
70-79 400,815 121.59 487 (13.6%) 104.57 419 (20.1%) 0.86 Stage IV
80+ 142,471 158.61 226 (6.3%) 153.32 218 (10.5%) 0.98 13.04%
* WHO Global Burden of Disease, 2004 update [7].
** INEN 2007-2011[12].
doi: 10.1371/journal.pone.0082575.t001
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developed by the WHO and sent to the study team leader
(INEN). Its results provided key data for our analyses and an
overview of the current breast cancer activities in Peru [12].
From a standard set of breast cancer control interventions
[17,18], the study team identified a set of 15 interventions
relevant to in the Peruvian context, all related to breast cancer
treatment, early diagnosis, screening or palliative care (Table
2). The study team introduced a particular intervention of
interest, relating to the diagnostic procedure of women with
palpable masses detected through clinical breast examination
(CBE) screening [25,26]. This intervention aims at improving
the capacity of early breast cancer diagnosis (i.e. confirmation
by triple test) during CBE screening, by using upfront fine
needle aspiration (FNA) first - instead of mammography first -
at the primary healthcare level (Figure S1). In this way, the
number of (technically more demanding) mammograms and
core biopsies at the primary healthcare level could be reduced.
The study team also adjusted standard treatment regimes of
previous WHO-CHOICE analyses, and added therapies for
HER2neu positive women (Trastuzumab). Furthermore,
various combinations of screening age groups
(40-69/40-64/45-69/45-64/50-69/50-64 years) and screening
frequencies (annually/biennially/triennially) were introduced for
the screening interventions. Additionally, the team defined
different screening interventions specifically for rural areas
(CBE screening vs. mobile mammography units in 40% of the
total population) and urban areas (e.g. only fixed
mammography units in 60% of the total population) according
to the Peruvian urbanization rate (60%).
We combined the 15 interventions to construct a total of 94
intervention scenarios. This includes the current Peruvian
situation in which patients of stages I to IV are treated at a 50%
coverage level, along with preventive counseling (30%
coverage) and opportunistic screening (15% coverage)[12].
Other interventions are evaluated at a geographic coverage
level of 60%, 80% or 95% (i.e. reaching 95% of those who
need services) according to standard CHOICE methodology.
Mathematical model
The model structure is presented in Figure 1 and includes a
healthy state, a deceased state, and stage I to IV breast cancer
states following the American Joint Committee on Cancer
(AJCC) [18,27]. To assess health outcomes, WHO-CHOICE
employs an epidemiological, population based approach. The
national breast cancer epidemiology is entered into a state
transition model, along with background birth, population, and
mortality rates, to estimate the total number of disability
adjusted life years (DALYs) experienced over the lifetime (100
years) of the Peruvian population [28]. The effectiveness of
interventions is expressed in changes in case fatality
(treatment interventions), health state valuations (HSVs), or
stage distribution (awareness raising and screening
interventions). Interventions are taken to be implemented for a
period of 10 years, after which epidemiological rates go back to
their counterfactual level of no intervention. The difference in
the total number DALYs lived by the population between each
scenario and the null-scenario gives the population health
gains in DALYs averted. Consistent with the WHO Global
Burden of Disease study, DALYs are discounted (at 3% per
year) and age weighted.
Effectiveness data
We based epidemiological data on the WHO Global Burden
of Disease (GBD) study, applied to the population of Peru of
2011 [5,7,29]. The impact of treatment in Peru was estimated
on the basis of stage specific survival rates (case-fatality) from
INEN (2000-2010) and previous WHO-CHOICE analyses
[18,30], whereas the impact of trastuzumab on case fatality
was based on the literature (Table 3) [31].
Health state valuations originate from disability weights
(DWs) of the GBD study, and we assumed that interventions
affect DWs in stage IV only. The DW for stage I is equal to the
GDB estimate, while for other stages the GBD long term sequel
(0,09) was adjusted according to quality of life estimates from
the literature [32,33]. The current stage distribution of women
presenting with breast cancer in Peru was derived from INEN
(2007-2011)[12], and the impact of the various screening
interventions on this stage distribution was estimated on the
basis of a model following Duffy et al. by using proportional
detection rates [34]. We applied a stage shift from developing
countries [17] to the Dutch screening program [35], and
corrected this shift for locally relevant attendance rates (72%)
and the Peruvian epidemiology and demography. The age
specific sensitivity of tests and sojourn times (CBE sojourn
times are two-third that of mammography) were based on the
literature [34-36]. The effectiveness of the awareness raising
interventions are based on a study from Malaysia [37] while we
assumed a twofold effect on stage distribution when applying a
mass media campaign.
Cost data
Following standardized WHO-CHOICE methodology on
CEA, we used an ingredients approach for our costing
analysis, in which prices and quantities are separately
reported. We distinguished patient-level and program-level
costs, and to estimate the total patient costs of interventions we
multiplied the unit costs of patient services with the number of
patients requiring these services.
Unit costs of patient services were based on the principles of
micro-costing, including detailed resource utilization patterns
and prices for each procedure (Table S1, Table 4). INEN
provided these unit cost to a great level of detail, except for the
cost of facilities (buildings, rooms) and the cost for the
transportation of drugs and supplies. We derived the
transportation multipliers, the size, price and annualization
factors for facilities, from a standard WHO-CHOICE database
and applied them to each eligible item [20].
We estimated the costs for the FNA intervention through a
patient management scheme from the international literature,
as this data was not yet available in Peru [38]. We then used
average weighted resource patterns for FNA, based on
observational studies from different countries [39-44], and
assumed similar final outcomes for both CBE screening with
upfront FNA and usual CBE screening (Figure S1).
Program-level costs capture management, administrative,
media and law-enforcement costs, and costs for training of
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healthcare personnel. These costs were based on estimates
from WHO-CHOICE and from Peruvian program managers
(INEN). Media and operating costs (i.e. prices for broadcasting,
flyers, and posters) were based on local inventories of prices,
also provided by INEN.
For all interventions, we also included costs of diagnostic
tests for women presenting with initial symptoms without breast
cancer (true-negatives), and assumed the ratio of tested
negatives vs. tested positives to be 16.4:1 in non-screened
populations and 21.5:1 in screened populations [45,46]. Single
treatment scenarios also include the costs of diagnosing all
other stages, and regarding screening interventions, we
included costs for evaluating false positives [47].
All costs were estimated in 2012 Peruvian Soles and
converted to U.S. dollars (US$) using the 2012 exchange rate
(1US$ = 2,603SOL). Both health effects (DALYs) and costs
(US$) were discounted at an annual rate of 3%.
Cost-effectiveness analysis
The average cost effectiveness ratio (ACER) for each
intervention is calculated by dividing the total costs of an
intervention by its corresponding effects, relative to the
comparator situation of no intervention.
In addition to these ACERs, incremental cost effectiveness
ratios (ICERs) are reported for the successive set of
interventions that can be purchased at expanding levels of
resource availability, starting with the intervention with the
lowest cost per DALY averted, then moving to the next most
cost-effective intervention. The order in which interventions can
be selected according to their ICER is called an expansion
path, and only interventions that are both more effective and
less costly than other (combinations of) interventions are
considered on this expansion path. The incremental cost-
effectiveness ratios (ICERs) for those interventions are
calculated by dividing the incremental costs by the incremental
health effects.
CEA results should be furthermore interpreted according to a
defined set of cost-effectiveness thresholds. WHO-CHOICE
denotes an intervention as “cost-effective” if it produces a
healthy year of life for less than three times the gross domestic
product (GDP) per capita, and as “very cost-effective” if it
produces a healthy year of life for less than the GDP per capita
(human capital approach) [48]. In Peru, this means that
interventions that cost less than $4,608 per DALY averted can
be considered very cost-effective, and interventions that cost
between $4,608 and $12,204 can be considered as cost-
effective.
Sensitivity Analysis
We performed a deterministic sensitivity analysis to assess
the robustness of the results to potential changes in key
assumptions regarding the model parameters. Based also on
Figure 1.  Graphical representation of the model.  Graphical representation of the model showing the relationships between the
different health states through the incidence rates of breast cancer (Ix1–Ix4), the different stage specific case fatality rates (Fx1–4),
and the background mortality (M). Stage specific relapse rates to stage IV were used to correct the disability weights (Rx1–Rx3).
doi: 10.1371/journal.pone.0082575.g001
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the results of previous sensitivity analyses [16-18], the baseline
case fatality rates and DWs were varied +/- 25% and we used
other sources for Peru’s current case fatality rates [12] and
current stage distribution [49]. The effect of awareness raising
interventions was reduced by 25%, and we lowered attendance
rates of screening interventions and the sensitivity of CBE and
mammography tests (-25%). Regarding costs, we varied the
transportation multipliers (+/- 25%), and varied the unit costs of
CBE and mammography (+/- 25%) as well as the costs for FNA
(+/- 25%).
Results
A total of 94 single and combined intervention strategies
were assessed and their annual cost, effects, and cost-
effectiveness are provided in Table S2 and shown graphically
in Figure 2.
Cost-effectiveness of breast cancer interventions and
expansion path according to ICER (Incremental cost-
effectiveness ratio). Dotted lines represent the cost-
effectiveness threshold of 3*GDP/capita/DALY averted (12.204
US$/DALY) and 1* GDP/capita/DALY (4.068 US$/DALY).The
annual treatment costs for breast cancer stages I to IV, vary
Table 4. Average utilization of main diagnostic and treatment services and unit costs per patient.
Procedure Ingredients Stage I Stage II Stage III Stage IV   
Palliative (SPC)
†   
Unit cost per
patient (US$)
Initial diagnosis
and evaluation
during treatment
Medical consultation 2 2 2 2  6.22
 Core biopsy procedure 1 1 1 1  45.02
 Specimen examination 1 1 1 1  9.76
 Bilateral Mammography 1 1 1 1  14.24
 Echo of breast 1 1 1 1  6.20
 Echo of abdominal/pelvic area 1 1 1 1  10.49
 Liver function tests 1 1 1 1  2.07
 Chest X-ray 1 1 1 1  6.79
 Bone scan 1 1 1 1  46.01
 CT of chest 1 1 1 1  96.37
 CT of abdominal/pelvic area 1 1 1 1  115.50
 Multidisciplinary consult 1 1 1 1  100.90
Treatment Pre-operative tests 1 1 1 -  86.57
 Surgical risk analysis 1 1 1 -  20.18
 Surgery 1 (lumpectomy)
1 (lumpectomy/
modified radical
mastectomy)
1 (modified radical
mastectomy) -  835.88 / 951.77
 Radiotherapy consult 1 1 1 1  7.64
 Radiotherapy planning & firstadministration* 1 1 1 1  224.20
 Radiotherapy sessionadministration* 32 29.6 24 12  23.36
 AC regimen** - 4 4 4  104.00
 Taxol regimen** - 12 4 4  134.47
 Hepatic tests - 12 12 12  22.14
 Renal tests - 12 12 12  39.38
 Coagulation tests - 12 12 12  115.40
 CT - 2 4 4  115.50
 Bone scan - 2 2 2  46.01
 % receiving endocrine treatment*** 1680 1680 336 336  0.18
 % receiving pain medication     1 9136.87
 % receiving emetics     1 1903.52
* Radiotherapy generally includes a dose of 50 Gy given in 10-35 fractions or boosts on an outpatient basis.
** The (neo) adjuvant chemotherapy combination regimen consists of AC-Taxol: AC given 3-weekly for 4 cycles followed by paclitaxel given weekly for 12 weeks or 4 weeks.
*** Endocrine therapy consists of 20 mg. tamoxifen per day for 5 years.
† Palliative care is only applied to stage IV patients. Standard Palliative Care (SPC) does not include home based visits. Medication includes Tramadol 50 ml, Morphine 0.02
mg, Fentanyl 50 mg, Parecoxib 40 mg, Triamcinolone 50 mg, Diazepam, Lidocaine, epidural injections, Omeprazol 40 mg, Haloperidol 5mg, Levosulpiride 25mg.
doi: 10.1371/journal.pone.0082575.t004
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between 7.1 million (treatment of stage I) and 23.0 million US$
(treatment of stage II). Treatment of all stages costs more than
$58 million (95% coverage) and expanding this by providing
trastuzumab in all stages costs an extra $25 million ($83.8
million in total), while the additional cost for providing
trastuzumab only in stage I&II is about $7 million ($65.4 million
in total). The additional costs for providing basic or extensive
palliative are $1.2 million and $1.6 million ($44.4 and $59.5
million in total) respectively, whereas awareness raising
interventions cost $59.8 million (BAR) and $56.0 million (MAR).
The costs of screening interventions generally increase with
the screening frequency, e.g. in age groups 40 to 69, the costs
are $74.3 to $101.5 million for annual screening strategies and
$63.4 to $71.4 for triennial screening strategies. Furthermore,
when age group 40 to 45 is included in the screening strategy
or annual screening frequencies are applied, costs increase
relatively more as compared to age group 65 to 69 and triennial
screening frequencies. Screening costs also increase when a
mobile screening component is applied, i.e. the costs per
mammogram or CBE with a mobile unit are about 20% higher.
The upfront FNA component reduces the costs of CBE
screening (as compared to the usual CBE screening strategy)
by an estimated $3.48 per women diagnosed (Figure S1). As a
result, CBE screening interventions combined with upfront FNA
have slightly lower patient costs but higher program and
training costs.
In the individual stage I to IV treatment interventions the
annual number of DALYs averted vary between 451 (stage IV)
and 2,900 (stage II). Jointly these interventions can avert 6,757
DALYs. The addition of trastuzumab to eligible women in stage
I&II only averts 313 extra DALYs (a total of 7,080 DALYs),
whereas providing trastuzumab to eligible women in all stages
can avert 1128 extra DALYs (a total of 7,895 DALYs). The
addition of palliative care, both basic (BPC) and extended
(EPC), only adds very few DALYs. Awareness raising
interventions, combined with treatment of all stages and
standard palliative care, avert between 5,306 (BAR) and
12,115 DALYs (MAR).
The various screening intervention combinations avert
between 6,000 and 18,000 DALYs, generally much more than
treatment interventions only. By increasing screening
frequencies and by widening age groups, screening
interventions can avert more DALYs. With regards to the age
group of screening, including the oldest age group (65-69)
seems to avert relatively more DALYs as compared to
including the youngest age group (40-45).
Annual screening through fixed (urban) and mobile (non-
urban) mammography units has the most health impact, and
can avert more than 18,000 DALYs when applied in age group
40 to 69 and combined with EPC.
Average cost-effectiveness ratios (ACERs) of the individual
treatment interventions range between $5,406 (stage I
treatment) and $48,5676 (stage IV treatment) per DALY
averted. Treatment of all stages costs $8,605 per DALY
averted costs around $10,000 per DALY averted when
trastuzumab is added. Palliative care interventions costs
$8,782 (BPC) and $8,832 per DALY averted (EPC).
With regards to current breast cancer program in Peru, the
ACER of this scenario (scenario 3) is $8,426 per DALY
averted. The ACER of mass media awareness raising (MAR) is
$5,650 per DALY, yet, basic awareness raising (BAR) costs
$13,713 per DALY.
Figure 2.  Cost-effectiveness frontier.  
doi: 10.1371/journal.pone.0082575.g002
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Screening intervention combinations have ACERs ranging
from $4,125 to $10,939 per DALY. The most cost-effective
screening intervention in our analysis is triennial fixed
mammography screening (age 45-69) in urban areas combined
with mobile mammography screening (age 45-69) in non-urban
areas, which costs $4,125 per DALY averted.
Figure 2 shows the cost-effectiveness thresholds of three
times ($12,204) and one time ($4,608) the Peruvian GDP per
capita per DALY averted (dotted lines). This figure and Table 5
also show the expansion path for breast cancer control, i.e. the
order in which interventions should be implemented at different
levels of resource availability on the basis of incremental cost-
effectiveness ratio (ICER). This path shows that triennial fixed
mammography screening (age 45-69) in urban areas combined
with mobile mammography screening (age 45-69) in non-urban
areas is the optimal choice ($4,125 per DALY averted, scenario
67), followed by triennial fixed mammography screening (age
40-69) in urban areas combined with mobile mammography
screening (age 40-69) in non-urban (ICER of $5,659 per DALY
averted, scenario 65). After that, the next best intervention that
follows from this expansion path is biennial mammography
screening (40-69 years) with fixed and mobile units (ICER
$27,477 per DALY, scenario 59). These screening
interventions are all combined with treatment of all stages and
standard palliative care (SPC). Eventually, annual fixed and
mobile screening combined with extended palliative care and
trastuzumab (scenario 94) is the most extensive intervention
with an ICER of $87,243 per DALY averted.
Note that of the aforementioned interventions, the ICERs of
only 2 interventions (scenario 67 and 65) are beneath the
proposed cost-effectiveness thresholds. Therefore, strictly
interpreted, they are the only candidates for implementation in
Peru according to the rules of allocative efficiency. Additionally,
other interventions (scenarios #4, #53, #55, #60, #83, #85,
#90-#93) are not on the expansion path (i.e. dominated) and
should therefore not be considered as well. However, as these
small differences in ICERs are likely not relevant at the policy
level, we nevertheless consider interventions on - and close to
- the expansion path as potential candidates for implementation
in Peru (Table 5).
Sensitivity Analysis
Sensitivity analysis showed that our model is most sensitive
to alternative assumptions on screening attendance and the
sensitivity of screening devices. Varying the case fatality rates
and current stage distribution also impacts our results, whereas
alternative assumptions on unit costs for FNA or
mammography, transportation multipliers or DW’s have less
impact (Table S3). Lowering screening attendance from 72% to
54% (-25%) would increase the ACERs with about 26%, while
lower test sensitivities of CBE and mammography screens
(-25%) would increase the ACERs with about 24%. If higher
case-fatality rates were assumed (+25%), representing poorer
survival, the ACERs of the interventions in table S3 would
increase about 22%. Lower case-fatality rates would result in a
15% decrease of these ACERs. Increased intervention costs
due to respectively higher unit costs of FNA, mammograms
and transportation multipliers (+25%) increase the ACERs
between 0% and 9%.
Discussion
We have quantified the health effects, costs, and cost-
effectiveness of a broad range of interventions for breast
cancer control in Peru. The results were obtained by means of
a dynamic population model, using consistent demographic
and epidemiological data of the populations, allowing general
comparisons of the costs and effects of the interventions
studied.
Our results provide important information on strategies for
breast cancer control in Peru and suggest that the current
situation in Peru could be improved through implementation of
triennial or biennial mammography screening strategies,
combined with treatment of all strategies and standard
palliative care. These strategies seem the most cost-effective
in Peru, and costs between $68 and $80 million per year.
Probably also cost-effective, but less expensive, are triennial
screening strategies through combining mammography and
CBE screening. These strategies, combined with or without
basic palliative care or upfront FNA, cost between $64 and $66
million per year. Annual screening strategies come with higher
cost to the healthcare system and with relatively lower effects
compared to tri- or biennial screening, and are therefore not
recommended from an economic perspective.
Of the abovementioned interventions, only triennial
mammography screening strategies can be labeled cost-
effective (scenario 67 and 65). However, considering the
uncertainty on the effectiveness of these interventions, and
considering the inappropriateness to use this threshold as the
sole criterion for choosing interventions at the policy level, we
suggest considering all the interventions near the expansion
path for planning (long term) strategies (Table 5). Besides the
efficiency aspects of the studied interventions, we believe the
choice of intervention should also relate to other aspects of the
health system such as budget impact, equity and feasibility.
These aspects are discussed below.
First, compared to mammography screening, CBE screening
with upfront FNA implies a simpler and technically less
demanding approach at the primary healthcare level. Although
the total costs of adding the upfront FNA component are
slightly higher (about $240,000 per year), patient costs can be
slightly reduced due to the lower costs of the FNA strategy
($3.48 saved per diagnosis) and the implementation of this
intervention has been demonstrated in a very rural area [25].
This intervention, which includes an awareness raising of signs
and symptoms component, could be recommended above
usual CBE screening strategies in Peru for feasibility reasons,
especially in rural areas.
Second, although treatment interventions are - on
themselves - not economically attractive, treatment is an
integral component of the continuum of care and essential to
be scaled up if any screening intervention is implemented. Only
60% of the Peruvian population is currently insured, creating
high barriers to accessing care for many Peruvians. Besides
treatment interventions, awareness raising of signs and
Efficiency of Breast Cancer Control in Peru
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Table 5. Recommended interventions according to their incremental cost-effectiveness ratio (ICER), position in expansion
path and budget impact.
Sce-
nario
number
(#) Intervention scenarios
Coverage
level (%)
Patients
per year
Annual
treatment
costs**
Annual
program
costs**
Annual
training
costs**
Annual total
costs**
Cost per
patient a
year**
DALYs
averted
a year***
DALYs
averted
per
patient
a
year*** ACER ICER
4 Stage I treatment &relapse only 95% 1,602 6,582,278 515,816 29,227 7,127,321 4,449 1,318 0,82 5,406 Dominated
85
Stage I to IV treatment
with triennial MIXED
screening: URBAN
(45-49 CBE) (50-69 MM
FIXED) 60%/ RURAL
(CBE 45-69) 40%*
95% 4,402 53,035,136 10,396,581 276,684 63,708,401 14,473 14,308 3,25 4,453 Dominated
83
Stage I to IV treatment
with triennial MIXED
screening: URBAN
(40-49 CBE) (50-69 MM
FIXED) 60%/ RURAL
(CBE 40-69) 40%*
95% 4,402 53,577,050 10,396,581 276,684 64,250,315 14,596 14,959 3,40 4,295 Dominated
89
Stage I to IV treatment
with most efficient
triennial MIXED:
URBAN (40-49 CBE)
(50-69 MM FIXED)
60%/ RURAL (CBE
40-69) 40%*+ FNA*
95% 4,402 53,557,982 11,208,251 292,272 65,058,506 14,779 14,959 3,40 4,349 Dominated
90
Stage I to IV treatment
with most efficient
triennial MIXED:
URBAN (40-49 CBE)
(50-69 MM FIXED)
60%/ RURAL (CBE
40-69) 40%* + FNA +
BPC
95% 4,402 53,539,583 12,511,232 518,783 66,569,598 15,123 14,961 3,40 4,450 Dominated
67
Stage I to IV treatment
with triennial
mammography
screening (45-69 years)
FIXED 60%/MOBILE
40%*
95% 4,402 54,944,080 13,423,175 350,727 68,717,982 15,611 16,657 3,78 4,125 4,125
91
Stage I to IV treatment
with most efficient
triennial FIXED/
MOBILE screening
strategy (FIXED/
MOBILE, 45-69) + BPC
95% 4,402 54,804,394 14,726,156 577,237 70,107,788 15,926 16,658 3,78 4,209 Dominated
65
Stage I to IV treatment
with triennial
mammography
screening (40-69 years)
FIXED 60%/MOBILE
40%*
95% 4,402 57,581,446 13,423,175 350,727 71,355,347 16,210 17,123 3,89 4,167 5,659
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symptoms (particularly in areas where breast cancer is
diagnosed in late stages) is imperative for early detection [50].
Also, if any form of early detection or screening is
implemented, patients need to be referred through to a
comprehensive system with low social and financial barriers.
This could partly be managed by reimbursing patients and their
families for travel and accommodation. Efforts to reach
universal coverage should therefore continue and a gradual
increase in coverage of current treatment services, along with
Table 5 (continued).
Sce-
nario
number
(#) Intervention scenarios
Coverage
level (%)
Patients
per year
Annual
treatment
costs**
Annual
program
costs**
Annual
training
costs**
Annual total
costs**
Cost per
patient a
year**
DALYs
averted
a year***
DALYs
averted
per
patient
a year*** ACER ICER
60
Stage I to IV treatment
with biennial
mammography
screening (40-64 years)
FIXED 60%/MOBILE
40%*
95% 4,402 62,065,226 15,710,263 370,211 78,145,701 17,752 17,338 3,94 4,507 Dominated†
59
Stage I to IV treatment
with biennial
mammography
screening (40-69 years)
FIXED 60%/MOBILE
40%*
95% 4,402 63,804,007 15,710,263 370,211 79,884,482 18,147 17,433 3,96 4,582 27,477†
55
Stage I to IV treatment
with annual
mammography
screening (45-69 years)
FIXED 60%/MOBILE
40%*
95% 4,402 74,070,789 17,997,352 389,696 92,457,837 21,004 17,385 3,95 5,318 Dominated†
53
Stage I to IV treatment
with annual
mammography
screening (40-69 years)
FIXED 60%/MOBILE
40%*
95% 4,402 83,070,430 17,997,352 389,696 101,457,478 23,048 17,857 4,06 5,682 Dominated†
94
Stage I to IV treatment
with most expensive
screening strategy
(annual, FIXED60%/
MOBILE40%, 40-69 ) +
EPC + trastuzumab (all
stages)
95% 4,402 103,306,498 19,638,424 625,949 123,570,871 28,072 18,737 4,26 6,595 87,243†
ICER: Incremental cost effectiveness ratio, ratio of additional cost per additional life-year saved when next intervention is added to a mix (additional US$ per additional DALY
saved). ACER: Average cost-effectiveness ratio compared to the do nothing-scenario (US$ per DALY averted). MIXED screening: combines both CBE screening and
mammography screening elements in the screening program. URBAN: program specified for urban population, covers about 60% of the total population. RURAL: program
specified for rural population, covers about 40% of the total population. CBE: clinical breast examination screening. MM: mammography screening. FIXED: screening
program based on fixed mammography units. MOBILE: screening program based on mobile screening unit. FNA: upfront fine needle aspiration program. BPC: basic
palliatice care program. EPC: extende palliative care program.
* These scenarios include Standard Palliative Care (SPC)
** In 2012 US$ (1 SOL = 0,384 US$)
*** DALYs, disability-adjusted life-years (age weighted, 3% discounted) . DALYs are averted over a 100 year period but attributed to the implementation period of 10 years.
† These interventions have ICERs higher than the 3 times GDP per capita per DALY threshold and can, strictly speaking, not be considered cost-effective.
doi: 10.1371/journal.pone.0082575.t005
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improvements of referral systems should first - or
simultaneously - be established in Peru.
Third, stage IV treatment only (including standard palliative
care (SPC)) is the least economically attractive intervention
(ACER of $48,576 per DALY), and generally palliative care
cannot be recommended from an economic perspective. If
management of stage IV patients entails home based visits
(BPC), patient costs slightly decrease due to a reduction of
hospitalization days. However, the extra training and program
cost for organizing this palliative service model outweigh these
savings and BPC is not cost-effective either. Nevertheless, this
intervention costs only slightly more than the current SPC ($1.2
million more) and allows patients to decease at home, where
family and friends are able to support and spend their last
moments with the patient. For this reason, and regarding the
many patients in advanced stages currently, it could be
meaningful to provide basic palliative care in Peru.
Fourth, the addition of trastuzumab to all eligible patients
(about 15% of all patients), is less economically attractive than
treatment of all stages (ACER of $10,620 vs. ACER of $8,605
per DALY). Moreover, it comes with an additional cost of over
$25 million ($83.8 million in total) - almost 45% higher than the
budget for treatment of all stages. If trastuzumab is given only
to eligible patients in stage I and II, this ACER is lower ($9,247
per DALY) and the additional costs are about 12% higher
($65.5 million in total). This intervention should therefore be
preferred if trastuzumab is added as a therapeutic option for
breast cancer control. The addition of trastuzumab to all eligible
patients is not recommended for Peru.
Fifth, breast cancer screening highly depends on the
availability of human resources, facilities and devices for proper
diagnosis and treatment. It is necessary to secure adequate
infrastructure, equipment and human resources before any
screening activities can commence. In addition, as the current
health system in Peru is fragmented and in a decentralization
process, it seems very difficult to achieve nationwide,
organized screening. If screening is provided by competitive
public and private actors, all with their own target populations in
the same areas, we recommend either law enforcement and
strong leadership to negotiate a plan with all these actors, or
installing a separate public operation that could provide the
entire screening programme. Attendance rates are perhaps
equally important for both the success of screening and the
equitable distribution of its health outcomes. In this, appropriate
education and information is essential and although most
screening studies show positive results on stage distribution in
developing countries [51-53], these interventions can easily fail
when education and information are neglected. Screening or
early detection communications strategies should also include
clear messages on the benefits and harms of the different early
detection modalities [50]. Our sensitivity analysis furthermore
showed that if attendance rates reduce from 72% to 54%, the
ACERs of screening interventions increase with 26%. We
therefore recommend a thorough evaluation of Peru’s current
screening activities, so these barriers become more
transparent and future screening programs can better
guarantee adequate attendance and equal access.
Sixth, mobile screening units are generally more accessible
in non-urban areas as opposed to fixed mammography units
and therefore more effective. Mobile screening could also lead
to a more equal distribution of health outcomes and could
therefore be considered if screening is implemented. However,
the costs for reaching out to the non-urban areas (30%-40% of
total population) by mobile units are high as the cost of each
screen increases with at least 20%. A combination of CBE
screening and mammography screening (mixed screening)
seems a cost-effective alternative with lower budget impact,
and less complex to implement in non-urban areas compared
to mobile mammography screening. Hence, we generally
recommend Peru to consider a mixed screening strategy (CBE
screening below 50 and mammography screening in women
older than 50 for urban areas, and CBE screening in all ages
for non-urban areas) for feasibility and budgetary reasons.
Seventh, and in general, the current budget for controlling
priority cancers in Peru (colo-rectal, stomach, cervical, breast,
prostate, lymphomas, leukemia) has been increased to over
$25 million for 2012 [11]. Despite this impetus, the full
implementation of the broad range of breast cancer
interventions already requires more budget. Treatment of all
patients with breast cancer would costs around $58 million per
year, and screening will at least cost another $5 million per
year. Moreover, the budget for (breast) cancer control also
faces competition with other healthcare interventions.
International literature suggests that interventions for
communicable diseases and preventive interventions for non-
communicable diseases are economically more attractive
compared to breast cancer interventions [20,54,55]. With
regards to the economic attractiveness of screening
interventions for other non-communicable diseases, breast
cancer screening seems to compare worse to cervical
screening but better compared to colorectal screening [16].
Yet, these international estimates should be carefully
interpreted for national level decision making. Given these
budgetary constraints, the MoH in Peru could decide to
implement less expensive interventions such as CBE
screening, mass-media awareness raising, or treatment only.
This would however introduce an inefficient use of resources
and instead we suggest to gradually expand the recommended
screening interventions, starting at lower -more affordable-
coverage levels. The MoH in Peru could for example first
increase treatment coverage and select an urban area to
demonstrate triennial CBE and mammography screening in
currently targeted women (45-64 years). In a non-urban area,
awareness raising and CBE screening could first be initiated
and combined with upfront FNA. Once a reasonable increase
in coverage is reached, the program could expand to screening
women 45 to 69 years, or 40-69 years old, possibly by mobile
units providing both mammography and CBE. These mobile
units could be shared for the screening and early detection
activities of the other priority diseases. The gradual expansion
will give extra time to train the required human resources and
to negotiate more budget for infrastructure and equipment.
Our study has a number of limitations. First, a national
cancer registry in Peru is not yet available and local data on
breast cancer epidemiology and patient resource patterns were
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derived from different sources. Breast cancer treatment
practices probably differ between the many public and private
institutions. Since our data was mostly based on composite
hospital data from the urban, public sector, our results may not
be representative for the whole country. These limitations
indicate the need to start a national cancer registry in Peru.
Second, evidence on the effectiveness of awareness raising,
CBE and mammography screening in Peru and many other
countries is absent. To arrive at Peruvian estimates we used a
model approach that has previously been applied in a range of
other studies and was also considered credible by the expert
panel in our study. Also, our sensitivity analysis shows that
using alternative assumptions on case fatality rates,
attendance rates or the sensitivity of screening devices lead to
significant differences in cost-effectiveness. A combined effect
of these factors could change the cost-effectiveness of the
interventions under study further. However, as these factors
have a similar impact on all interventions under study, it is
unlikely that this combined effect would change our study
conclusions. Despite these limitations, the results of our model
show similarities with results from other models [52,56,57].
Third, as information on the patient resource patterns of the
upfront FNA strategy was limited in Peru, we assumed similar
final outcomes for both CBE screening with upfront FNA and
the usual CBE screening strategy (i.e. the number benign or
malignant outcomes in both arms in Figure S1). However, FNA
could also cause structural distortions that may render further
imaging accuracy. Fourth, in the absence of reliable data and
following the health care perspective of the Peruvian MoH, we
did not include travel costs or productivity losses of patients
seeking or undergoing care. Including these cost would have
probably led to increased cost generally, and particularly for
women with advanced stage breast cancer [58,59]. WHO-
CHOICE analyses aim to provide broad indications of cost-
effectiveness on a range of interventions to inform general
policy discussions rather than to deliver very precise estimates
on a specific intervention and the above limitations are a
manifestation of this.
Conclusions
In summary, taking in consideration cost-effectiveness and
other factors, our analysis suggests that CBE screening with
upfront FNA in non-urban settings (age 40-69), combined with
both CBE and fixed mammography screening in urban settings
(age 40-69), could be a preliminary, cost-effective and feasible
option for Peru. A combination of fixed and mobile
mammography screening, due to its high budget impact and
the challenging implementation characteristics, should perhaps
be preferred on the long term when the economic and health
system conditions improve. However, whichever screening
modality is used, awareness raising of signs and symptoms,
cancer diagnosis, cancer treatment and basic palliative care
services should be improved simultaneously and barriers to
early detection and breast cancer care along the continuum
should also be explored and dissolved. As population based
screening programs are very complex and resource intensive,
particularly mammography screening, we suggest Peru to
focus initially on triennial screening in women currently targeted
(age 45-64) in urban and non-urban demonstration areas and
gradually expand to the proposed program. Annual screening
strategies, late stage treatment and trastuzumab therapy are
generally not economically attractive.
Supporting Information
Figure S1.  Comparison of usual CBE screening strategy
and CBE screening with upfront FNA, and level of
execution. CBE screening with upfront FNA (fine needle
aspiration): after a positive CBE screen (about 4% of the CBE
screened population) women receive FNA. Depending on the
FNA test results, mammography (MM) or core needle biopsy
(CNB) is performed as part of the triple test (physical
examination, mammography, needle biopsy) for final breast
cancer diagnosis.
(TIF)
Table S1.  Example of micro costing study results (i.e. core
biopsy), and their modifications in Peru.
(DOCX)
Table S2.  Costs (US$), effects and cost-effectiveness of all
analyzed breast cancer control interventions in Peru.
(DOCX)
Table S3.  Results of sensitivity analysis on average cost-
effectiveness ratios (ACERs) of recommended
interventions.
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